New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT05163041

First seen Jan 18, 2026 · Last updated May 07, 2026 · Updated 15 times

Summary

This study tests a new drug called BT7480, alone or with another drug (nivolumab), in about 200 people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors or slows cancer growth. Participants must have tumors linked to a protein called Nectin-4, such as certain bladder, lung, or ovarian cancers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University Irving Medical Center

    New York, New York, 10032, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • START Center for Cancer Care

    San Antonio, Texas, 78229, United States

  • State University of Iowa

    Iowa City, Iowa, 52242, United States

  • The Beatson West of Scotland Cancer Centre

    Glasgow, G12 0YN, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    Sutton, Surrey, SM2 5PT, United Kingdom

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • Virginia Cancer Specialists

    Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.